

BIOCENTURY

BayHelix
G R O U P

In collaboration with:

**McKinsey
& Company**

*Organized by BioCentury and BayHelix
in collaboration with McKinsey & Company*

The BioCentury-BayHelix

EAST-WEST BIOPHARMA SUMMIT

NOV
14-16
2022


REDWOOD CITY,
CALIFORNIA

NOV
17-18
2022

VIRTUAL



GRAND BAY SAN FRANCISCO
Redwood City, California



BioCenturyEastWest.com



Dear Colleague:

For almost a decade, BioCentury and BayHelix and our partners have brought together a global community of C-suite executives and investors focused on biopharma innovation and cross-border collaboration. But the world has changed: Emerging Biopharmas in the U.S., Europe and Asia now face the same dilemma: How do you globalize to deliver innovation to patients and achieve an ROI for investors?

- A handful of biopharma companies will build global operations.
- Most will achieve global economics through partnering and licensing.
- Others will capture a share of the economics by enabling global development and financing.
- And all will require trusted cross-border relationships for success.
- The East-West Biopharma Summit is designed to help biopharma decision makers and investors rise to the Challenges of Globalization, understand globalization strategies and form trusted cross-border relationships.

Topics include:

- Recruiting and retaining diverse cross-border management teams.
- Accessing world-class investors in the U.S., Europe, and Asia.
- Building and financing a MRCT (multiregional clinical trial) strategy.
- Navigating regulatory sea changes in the U.S., Europe, and Asia.
- Choosing between partnering and M&A to globalize product development and commercialization.
- Deciding whether or when a physical presence is required overseas.
- And much more....

Please join us for:

- Two days of strategic sessions to help busy executives understand successful globalization strategies.
- C-level networking: Build relationships with biopharma decision-makers and investors in an intimate setting.
- Four days of 1x1 meetings: Two days in person; two days virtual.
- Road Show presentations from rising biotechs in the East and West, selected by BioCentury.
- Digital option: Attend in-person or virtually via digital platform.
- Prep in Advance: Use BioCentury's BCIQ platform to research data (pipelines, financings, deals) and BioCentury analysis to help prepare for your 1x1 meetings.

We hope to see you in November at the BioCentury-BayHelix East-West Biopharma Summit!

Sincerely,



David Flores
CEO
BioCentury



Guo-Liang Yu, Ph.D.
Chairman
The BayHelix Group



THANK YOU TO OUR ORGANIZING COMMITTEE



CHAIRMAN:
STEVE YANG, PH.D.
Co-CEO
WuXi AppTec



JUN BAO, PH.D.
President & CEO
Impact Therapeutics Inc.



YONG BEN, M.D.
Clinical Advisor
BeiGene Ltd.



JOSHUA BERLIN
Head of Business
Development
BioCentury Inc.




KAREN BERNSTEIN, PH.D.
Co-Founder & Chairman
BioCentury Inc.



TONY CHEN
Partner
Jones Day



SIMONE FISHBURN, PH.D.
Vice President & Editor in
Chief
BioCentury Inc.



DAVID FLORES
Co-Founder,
President & CEO
BioCentury Inc.



THOMAS HERGET
Head of Silicon Valley &
China Innovation Hub
Merck Group



KEWEN JIN, M.D.
Managing Partner
Serica Partners




FRANCK LE DEU
Senior Partner & Head
of Greater China
Healthcare Practice
McKinsey & Company



WENDY PAN, PH.D.
Partner
Goodwin Procter



Rajesh Parekh
Senior Partner
McKinsey & Company



Kiran Reddy
Senior Managing Director
Blackstone



VICTOR SHI, PH.D.
Chairman
careLYFE



LIN SUN-HOFFMAN, PH.D.
Partner
**Liu, Zheng, Chen &
Hoffman LLP**



JONATHAN WANG
Chairman & CEO,
Inmagene, and
Co-Founder, **BayHelix**



GUO-LIANG YU, PH.D.
Chairman & CEO,
Apollomics Inc. and
Chairman, **BayHelix**



DEBRA YU, M.D.
President & Chief
Strategy Officer
LianBio



DAN ZHANG, M.D.
Co-Founder,
Director & CSO
ClinChoice Inc.



JIMMY ZHANG, PH.D.
Founder & CEO
Vinta Bio Inc.

NOV
14-16
2022REDWOOD CITY,
CALIFORNIANOV
17-18
2022

VIRTUAL




PRELIMINARY LIST OF ATTENDEES — WHO YOU WILL MEET

3E Bioventures Capital
3T Biosciences
6 Dimensions Capital
7G Bioventures
AbbVie Inc.
Abingworth LLP
Acclime USA
Acclime Australia
Actio Biosciences Inc.
Actym Therapeutics Inc.
Adcentrx Therapeutics Inc.
Adiso Therapeutics Inc.
Aditum Bio
Affamed Therapeutics
Asieris Pharmaceuticals
AWEX
Agi Capital & Business Solutions
Amgen
AnHeart Therapeutics
Antengene Corporation Ltd.
Apollomics Inc.
Argenx
Ashvattha Therapeutics Inc.
Atriva Therapeutics Inc.
AUM Biosciences
BAKX Therapeutics
Bay City Capital
BayHelix
BeiGene Ltd.
Bennu BioScience
Berkeley Center for Law and Technology
BioAge Labs
BioAi Health
BioCentury Inc.
BioInvent International AB
BioMarin Pharmaceutical Inc.
Biorchestra Co. Ltd.
Biosion Inc.
Bio-Techne
Biotheus Inc.

BirdoTech
Blackstone Life Sciences
BlossomHill Therapeutics
Bluejay Therapeutics
BridgeBio
Caidya
California Life Sciences
CanSino Biologics Inc.
careLYFE
Cargene Biopharma Inc.
CBC Group Investment Management Ltd.
Cellares
Chemical.AI
ChinaBio

Circle Pharma
Claritem Advisors
ClinChoice Inc.
Colliers International
Connect Biopharmaceuticals Ltd.
Cravath, Swaine & Moore LLP
CTIC Capital
Cytokinetics
D2M Biotherapeutics
Davis Polk
DCVC
Devonian Health Group Inc.
Duality Biologics
EdiGene Bio USA Inc.

Recent Registrants for the East-West Biopharma Summit



**PRELIMINARY LIST OF ATTENDEES — WHO YOU WILL MEET**

eFFECTOR Therapeutics	Liu, Zheng, Chen & Hoffman LLP	Protagonist Therapeutics
Eight Roads Ventures	Luca Healthcare	Proteologix Inc.
Eluminex Biosciences Ltd.	Lumos Pharma Inc.	Pureos Bioventures
ENSEM Therapeutics Inc.	Lychee Group	Qiming
Enveda Biosciences	Lyfe Capital Ltd.	Quan Capital
Esco Lifesciences Group	MAIA Biotechnology Inc.	Quintara Discovery
Flanders Investment and Trade	Marengo Therapeutics Inc.	Rani Therapeutics
Frazier Life Sciences	McKinsey & Company Inc.	RDPAC
Generate Biomedicines	Medikine	Renexes LLC
Genome Insight	MEDIPOST Co., Ltd.	ReviR Therapeutics Inc.
Germfree Laboratories Inc.	Merck & Co. Inc.	Roche
GlaxoSmithKline	Merck KgaA	Russell Reynolds Associates
Goodwin Procter LLP	Mirati Therapeutics Inc.	SAPA
Guardant Health	MiRXES Pte. Ltd.	Senti Biosciences Inc.
HanchorBio Inc.	MSQ Ventures	Serica Partners
HillGene BioMedical Development Ltd.	Nan Fung Life Sciences	Shanghai Junshi Biosciences Co. Ltd.
HM Capital	NB Health Laboratory Co. Ltd.	Shonan iPark (Takeda Pharmaceutical)
HuiGene Therapeutics	Neoleukin Therapeutics Inc.	ShynianBio
HuiMei Capital	NeuCyte	Sidley Austin LLP
Hummingbird Bioscience Pte. Ltd.	Neumora Therapeutics Inc.	Sincere Pharmaceutical Group Ltd.
Hutchmed	NeuShen Therapeutics	Sinogen Biopharma Inc.
I-Mab Biopharma	Novartis	Sofinnova Investments
Illumina Ventures	Novome Biotechnologies	SPH Bio
Immune-Onc Therapeutics Inc.	Novotech CRO	Spotlight Therapeutics Inc.
Impact Therapeutics Inc.	Nuance Pharma Co. Ltd.	SR One Capital Management
IN Therapeutics Inc.	Nucleus Network	Stanford University
Inmagene Biopharmaceuticals Co. Ltd.	Oculus SA	Structure Therapeutics
Innovent Biologics	OncXerna Therapeutics Inc.	TAE Life Sciences
Insilico Medicine Inc.	Origami Therapeutics Inc.	Taiho Ventures LLC
iPark Shonan (Takeda)	Otsuka Pharmaceutical Co. Ltd.	The Shelburne Group
Jacobio Pharmaceuticals Co. Ltd.	Overland Pharmaceuticals	Third Rock Ventures
Johnson and Johnson	Panacea Venture	TopAlliance Biosciences Inc.
Jones Day	Panorama Medicine	TPG Life Sciences Innovations
Kinarus Therapeutics	Paul Hastings LLP	Triastek Inc.
Lake Bleu Capital	Phagelux	Trillium Medical Ventures
Lee's Pharmaceutical Holdings Ltd.	PharmaBlock	Unicycive Therapeutics
Legend Biotech	Pharus Diagnostics	Unicorn Capital Partners
LEO Pharma A/S	Phil Rivers Technology	University of California at Berkeley
LianBio	PhIRDA	Vinta Bio Inc.
Lightspeed Venture Partners	Pivotal BioVenture Partners	
LingMed Ltd.	Pivotal Life Sciences	



SCHEDULE-AT-A-GLANCE

Monday, November 14, 2022

- 5:00 pm General Registration Opens
- 6:00 pm Welcome Remarks—Day 1
- 6:15 pm Keynote: Creating Breakthroughs – What Will Define Successful Biotech Companies of the Future?
- 7:15 pm Welcome Reception sponsored by Panacea Venture

Tuesday, November 15, 2022

- 8:00 am Registration & Continental Breakfast
- 8:45 am Welcome Remarks from BioCentury & The BayHelix Group
- 9:00 am BioCentury Scene Setter Report: Does East-West Matter?

Concurrent: 1x1 Meetings – 30min sessions
- 10:00 am Concurrent: Presenting Company Track Begins
- 10:00 am Morning Networking & Refreshment Break
- 10:30 am CEO Roundtable: What Will it Take to Be Successful in the Next Era of Biotech?
- 11:30 am BayHelix Awards Presentation
- 12:00 pm Networking Lunch
- 1:30 pm Talent Showcase: Recruiting and Retaining Diverse Cross-Border Management Teams
- 2:30 pm Concurrent Workshops:

I. Global Development Workshop: How to Build and Finance an East-West MRCT Strategy

II. Hot Topics Workshop: The -Omics Promise: Why This Time is Different
- 3:30 pm Afternoon Networking & Refreshment Break

****The East-West Biopharma Summit schedule-at-a-glance and agenda is subject to change. For up to date information, please visit us online at: BioCenturyEastWest.com****

4:00 pm Concurrent Workshops:

Session I: Phase 1 Trials: How to Globalize to Accelerate Value Inflection

Session II: Regulatory Workshop: How to Operate Under China's Version of the Hatch-Waxman Act

5:00 pm 1x1 Meetings – Day I Concludes

Happy Hour Fire-side Chat: Globalizing R&D and Patient Access: A CEO's Perspective

5:30 pm Networking Reception & Dinner sponsored by Novotech

6:00 pm (CST) China Virtual Delegation in person Networking Reception at POP Rooftop Brasserie and Bar in Shanghai

Wednesday, November 16, 2022

- 8:00 am Continental Breakfast
- 9:00 am Capital Markets Showcase: Strategies for Success After the Bear Market

Concurrent: 1x1 Meetings – 30min sessions
- 10:00 am Morning Networking & Refreshment Break
- 10:30 am Concurrent: Presenting Company Track Begins

Concurrent Plenary Sessions:

Session I: The Merging of Finance and Entrepreneurship

Session II: Hot Topics Workshop: How to Globalize Access to Cell & Gene Therapies
- 11:30 am Strategy Workshop: Planting Footprints Abroad
- 12:15 pm Networking Lunch
- 1:15 pm Concurrent Sessions:

Session I: Capital Markets Showcase Workshop: A Mountain of Dry Powder

Session II: Hot Topics Workshop: Biopharma AI Scorecard
- 2:15 pm What's Next on the Bridge to Innovation
- 3:00 pm Closing Networking Reception



AGENDA

Monday, November 14, 2022

- 5:00 pm General Registration Opens
- 6:00 pm Welcome Remarks from BioCentury & The BayHelix Group
- 6:15 pm **Keynote: Creating Breakthroughs – What Will Define Successful Biotech Companies of the Future?**

The global biotech industry is at an inflection point with significant innovation on the horizon, and companies are exploring new technologies and business models that aim to achieve success in the future ecosystem. BioCentury's Insights Partner McKinsey & Company debuts its report on the future of the global biotech industry, including trends and future perspectives spanning key themes of platform technologies, the role of AI, and how globalization can create value by addressing significant unmet need. Access to the report will be available to BioCentury East-West Summit attendees.

Session Chairs:

Olivier Leclerc, Senior Partner, McKinsey & Company
Rajesh Parekh, Ph.D., Senior Partner, McKinsey & Company

- 7:15 pm Welcome Reception

sponsored by:



Tuesday, November 15, 2022

- 7:00 am Summit Fun Run / Yoga & Meditation
- 8:00 am Registration & Continental Breakfast
- 8:45 am Welcome Remarks – Day I
- 9:00 am **BioCentury Scene Setter Report: Does East-West Matter?**

BioCentury's annual analysis measures the appetite of biotechs and their investors for globalizing the value of their investments. How and where are companies planning to commercialize their lead assets? Will it get easier or harder to strike cross-border deals? And what do the next five years hold for companies

globalizing development programs for patients in the East and West? This panel will discuss the trends and issues raised by a survey of East and West stakeholders.

Session Chair:

Simone Fishburn, Ph.D., Vice President and Editor in Chief, BioCentury

Panelists:

Chris Carpenter, Executive Partner, Sofinnova Investments
Henk Joos, Ph.D., General Manager, Agio Capital & Business Solutions
Thomas Herget, Ph.D., Head, Silicon Valley & China Innovation Hub, Merck KgAA
Debra Yu, M.D., President & Chief Strategy Officer, LianBio

- 10:00 am Concurrent: Presenting Company Track Begins
- 10:00 am Morning Networking & Refreshment Break
- 10:30 am **CEO Roundtable: What Will It Take to Be Successful in the Next Era of Biotech?**

How can biotechs globalize to deliver innovation to patients in the East and West and maximize company value? In the Summit's 9th annual CEO plenary, join our Insights Partner McKinsey & Company to hear from biotech CEOs across the U.S., Europe, and Asia as they share their views and debate strategies for success in an uncertain future.

Session Chairs:

Jennifer Heller, Ph.D., Partner, McKinsey & Company

Panelists:

Vishal Doshi, CEO, AUM Biosciences
Riad Sherif, CEO of Oculis
David Meek, CEO, Mirati Therapeutics Inc.
J. Jean Cui, CEO, BlossomHill Therapeutics
Peter Bisgaard, Managing Director – Nan Fung Life Sciences, Pivotal Life Sciences



11:30 am BayHelix Awards Presentation

For the 13th year, BayHelix celebrates outstanding individuals and companies for achievements and contributions to the China and cross-border healthcare ecosystem: R&D Achievement of the Year; Deal of the Year; Commercial Achievement of the Year; Company of the Year; Woman Leader of the Year.

12:00 pm Networking Lunch

1:30 pm Talent Showcase: Recruiting and Retaining Diverse Cross-Border Management Teams

Ensuring diversity, equity and inclusion is a special challenge for biotechs with global aspirations. For them, diversity also means recruiting and nurturing management teams that span continents and time zones. How can biotechs succeed in what has become a global war for talent?

Session Chair:

Yvonne Lu, Co-Lead, Global Biopharma Practice, Russell Reynolds

Panelists:

Charlene Liao, Ph.D., President & CEO, Immune-Onc Therapeutics

Kathy He, Chief Executive Officer, Cargene Therapeutics
Carolyn Ng, Partner & Managing Director, TPG

2:30 pm Concurrent Workshops:

I. Global Development Workshop: How to Build and Finance an East-West MRCT Strategy

Regulators around the world have made clear that developers should conduct multi-regional clinical trials to ensure study results represent local patient populations and standards of care. This workshop will explain how biotech R&D leaders should approach this mandate.

Session Chair:

Barry Murphy, Chief Commercial Officer, Novotech

Panelists:

Peony Yu, M.D., Chief Medical Officer, Apollomics

Ke Liu, M.D., Ph.D., Chief Development Officer, Marengo Therapeutics

Marengo Therapeutics

Patricia Keegan, M.D., Chief Medical Officer, Junshi

Roger Luo, Ph.D., Chief Development Officer, Overland Pharmaceuticals

II. Hot Topics Workshop: The -Omics Promise: Why This Time is Different

Multi-discipline -omics promise layers of solutions for treating patients globally well beyond the dimensions of genomics alone, but is there reason to believe these technologies can usher in the much-awaited era of Precision Medicine? This session will discuss the prospects of multi-omics to identify targets, stratify clinical trials and personalize care, as well as the challenges of building diverse databases that represent global needs.

Session Chair:

Selina Koch, Ph.D., Executive Editor - BioCentury

Panelists:

David Goldstein, Ph.D., CEO, Actio Biosciences Inc.

John Lepore, M.D., SVP & Head of Research, GlaxoSmithKline

David Reese, M.D., EVP, Research & Development, Amgen

Paul Hoerbelt, Ph.D., Associate, Illumina Ventures

3:30 pm Afternoon Networking & Refreshment Break

4:00 pm Concurrent Workshops:

Session I: Phase 1 Trials: How to Globalize to Accelerate Value Inflection

Investors want early-stage biotechs to enter the clinic quickly. Many expect first-in-human data within a year. This workshop explores how U.S. and Asian biotechs have leveraged global sites, including Australia, to extend cash runway and achieve Phase 1 value inflection.

Session Chair:

Chris Hickey, EVP, Nucleus Network

Panelists:

Kiran Reddy, M.D., Senior Managing Director, Blackstone Life Sciences

Stewart Walker, President & Director, Acclime USA

Nishit Modi, Ph.D., Senior Vice President, Protagonist Therapeutics

Arvinder Dhalla, Ph.D., VP Clinical Development, Rani Therapeutics

NOV
14-16
2022REDWOOD CITY,
CALIFORNIANOV
17-18
2022

VIRTUAL

AGENDA

Session II: Regulatory Workshop: How to Operate

Under China's Version of the Hatch-Waxman Act

China launched its version of the Hatch-Waxman Act in July 2021 to govern drug patent exclusivity and patent term extension. Fifty new drugs have faced generic patent challenges so far. To maximize the partnership value of therapeutics in China, Western biopharmas need to read between the lines of Article 76 of China's Patent Law and closely follow the outcomes of Hatch-Waxman style disputes in China.

Session Chair:

Tony Chen, Partner, Jones Day

Panelists:

David Kappos, Partner, Cravath, Swaine & Moore LLP, and former Under Secretary of Commerce & Director, United States Patent and Trademark Office
Mark Cohen, Distinguished Senior Fellow, University of California at Berkeley, and former Senior IP Attache, U.S. Embassy - China

5:00 pm 1x1 Meetings – Day I Concludes

Late-Breaking Session:
Happy Hour Fireside Chat
Globalizing R&D and
Patient Access: A CEO's Perspective

5:30 pm Networking Reception & Dinner
sponsored by:



VIP NETWORKING RECEPTION

CHINA DIGITAL ATTENDEES

NOV. 15, 2022 6 PM—9 PM CST

While many of our friends in the East will join our strategic panels and 1x1 partnering meetings virtually, we invite virtual attendees in the Shanghai area to join us for this exclusive opportunity to network in person at the **POP Rooftop Brasserie and Bar**.*

** Space is limited and open to registered digital attendees.*

Wednesday, November 16, 2022

8:00 am Continental Breakfast

9:00 am **Capital Markets Showcase:**
Strategies for Success After the Bear Market

The future favors the "prepared mind." Biotech CEOs and investors in both the East and West have no choice but to prepare now to take advantage of opportunities to succeed after the Bear goes back into hibernation. What will be the signs of Spring they need to see from Wall Street to Hong Kong?

Session Chair:

Kiran Reddy, M.D., Senior Managing Director, Blackstone Life Sciences

Panelists:

Simeon George, M.D., CEO & Managing Partner, SR One
James Lin, Partner, Davis Polk
Sree Kant, Founder & CEO, Bakx Therapeutics
Shelley Chu, M.D., Ph.D., Partner, Lightspeed Venture Partners

10:00 am Morning Networking & Refreshment Break



AGENDA

10:30 am	<p>Concurrent: Presenting Company Track Begins</p> <p>Concurrent Sessions:</p>	<p>11:30 am</p> <p>Strategy Workshop: Planting Footprints Abroad</p>
	<p><u>Session I: The Merging of Finance and Entrepreneurship</u></p> <p>From newco incubation to entrepreneurs in residence, from entrepreneur-sponsored SPACs to investor-turned-founder, the merging of finance and entrepreneurship is growing. This session, led by a former OrbiMed partner turned CEO, examines how this trend is facilitating the growth of the bioindustry.</p> <p><u>Session Chair:</u> Jonathan Wang, Ph.D., Chairman & CEO, Inmagene Biopharmaceuticals</p> <p><u>Panelists:</u> James Huang, Managing Partner, Panacea Venture Scott Megaffin, CEO, Adiso Therapeutics, Inc. Tao Fu, Venture Partner, Frazier Healthcare Partners Jeff Calcagno, Head, JLABS Bay Area, Johnson & Johnson Innovation</p> <p><u>Session II: Hot Topics Workshop: How to Globalize Access to Cell & Gene Therapies</u></p> <p>Price is not the biggest hurdle to ensuring global access to cell and gene therapies – logistics, manufacturing and regulation are just some of the obstacles companies face before they get to revenues. Drivers of the next generation products discuss the strategies that will mark success, and whether the future of cell and gene therapies will be determined by East-West competition or collaboration.</p> <p><u>Session Chair:</u> Coleen Klasmeier, Partner, Sidley Austin LLP</p> <p><u>Panelists:</u> Qiutang Li, Ph.D., Chief Scientific Officer, Neurophth (Wuhan) Biological Technology Ltd Eric Davis, Chief Legal Officer, BioMarin Pharmaceutical Inc. Fabian Gerlinghaus, Co-Founder & CEO, Cellares Paul Hastings, CEO, Nkarta Inc.</p>	<p>Global strategists must make choices about how to build value offshore. In some cases, biotechs have chosen to create a physical presence in key markets. This session provides lessons from Asian biopharmas with outposts in the U.S. and Europe, and from Western biopharmas with outposts in Asia.</p> <p><u>Session Chair:</u> James Huang, Ph.D., Managing Partner, Panacea Venture</p> <p><u>Panelists:</u> Joan Shen, M.D., Ph.D., Founder & CEO, Neushen Therapeutics Inc. Kevin Oliver, Ph.D., Chief Operating Officer, U.S. and Europe & SVP, Global Head of BD&L, Simcere Pharmaceutical Group Ltd. Mark Lotter, CEO, Nuance Biotech Leonard Blum, President & CEO, XWPharma Melita Sun Jung, Chief Business Officer, Structure Therapeutics</p> <p>12:15 pm Networking Lunch</p>
		<p>1:15 pm</p> <p>Concurrent Sessions:</p> <p><u>Session I: Capital Markets Showcase Workshop: A Mountain of Dry Powder</u></p> <p>Chinese investors have long deployed USD into China biotechs and increasingly into U.S. and European companies. As Chinese investors seek to diversify investment opportunities, what does this mean for Western biotechs aiming to find funding?</p> <p><u>Session Chair:</u> Debra Yu, M.D., President & Chief Strategy Officer, LianBio</p> <p><u>Panelists:</u> Lan Kang, Managing Director & Head of Portfolio Management, CBC Group Sameer Rohatgi, Venture Partner, Lyfe Capital Judith Li, Partner, LAV Blake Salisbury, SVP, Business Development, Innovent Biologics</p>



Session II: Hot Topics Workshop: Biopharma AI

Scorecard

From Silicon Valley to Shenzhen, where is real progress being made in applying AI to drug discovery and development. This session will discuss the points along the drug development continuum where data science and machine learning can be a difference-maker in creating therapies for patients globally.

Session Chair:

Karen Tkach Tuzman, Ph.D. Senior Editor, Head of Discovery & Preclinical Development, BioCentury

Panelists:

Michelle Chen, Ph.D., Chief Business Officer, Insilico Medicine

Tom Chittenden, Ph.D., Dphil., Chief Scientific Officer, BioAi Health

Gevorg Grigoryan, Ph.D, Co-Founder & Chief Technology Officer, Generate Biomedicines

Aaron Arvey, Ph.D., Director, Machine Learning, Third Rock Ventures

Kiersten Stead, Ph.D., Managing Partner, DCVC Bio

2:15 pm

What's Next on the Bridge to Innovation

For 9 years, BayHelix, BioCentury and McKinsey & Company have tracked how Chinese Sea Turtles have created an innovation ecosystem at home. Now, many of the pathfinders are looking to extend their reach. In this session, BayHelix leaders will explore how mobile Chinese entrepreneurs and investors will contribute to global innovation.

Session Chair:

Jimmy Zhang, Ph.D., former Chairman, BayHelix; and Founder, Chairman & CEO, Vinta Bio Inc.

Panelists:

Wendy Pan, Ph.D., Partner, Goodwin

Lingshi Tan, Ph.D., Chairman & CEO, Caiyda

Stella Xu, Ph.D., Managing Director, Quan Capital

Hui Li, Ph.D, Founder, President & CEO, Adcentrx Therapeutics

Echo Hindle, Founder and CEO, MSQ Ventures

DIGITAL SESSIONS ONDEMAND

available beginning Nov 5

biocenturyeastwest2022.meeting-mojo.com

7th Annual Heads of R&D Roundtable: Prioritizing Your Portfolio for Globalization

As biotechs pursue out-licensing to create value and reach patients in both the East and West, C-Suite leaders must generate a portfolio of assets with globally competitive data. In the Summit's 7th R&D Roundtable, "Scientist CEOs", and Heads of Research and Business Development discuss how R&D strategy is evolving to meet this higher bar.

Session Chair:

Steve Yang, Ph.D., Co-CEO, WuXi Apptec

Panelists:

Lai Wang, Ph.D., Global Head of R&D, BeiGene

Ning Xia, Ph.D., Founder & CEO, Chemical.AI

Michael Shi, M.D., Ph.D., EVP, Head of R&D and Chief Medical Officer, Hutchmed

Lihan Zhou, Ph.D., Co-Founder & CEO, MiRXES Pte. Ltd.

Shirley Zhao M.D., Co-Founder & CEO, Bennu Biotherapeutics

3rd Annual Davis Polk C-Suite Bootcamp: Developing Routes to Global Capital

To maximize access to the capital markets, biotechs need to think globally when developing listing strategies. What dual-listing approaches can help tap liquidity across markets? How should executives prepare for the next favorable financing window in East and West? How can Asian companies comply with evolving auditing requirements and avoid de-listing risks? This workshop will guide both Western and Asian biotechs looking to globalize their investor base as well as their product pipelines.

Session Chairs:

Xuelin (Steve) Wang, Partner, Davis Polk

JAMES C. Lin, Partner, Davis Polk

Panelists:

Marietta Wu, Ph.D., Managing Director, Quan Capital

Ying Huang, Ph.D., CEO, Legend Biotech

Xin Liu, Partner, Eight Roads Ventures China

NOV
14-16
2022REDWOOD CITY,
CALIFORNIANOV
17-18
2022

VIRTUAL

PhIRDA/RDPAC Workshop: A Path Forward for China Innovators?

In recent years, China has rapidly developed policies to support biopharma innovation. What are the next steps required to encourage breakthrough innovations in China and to enable China-originated innovation to reach patients outside of China?

Session chair:

Dianna Qian, Partner, Pivotal BioVenture Partners

Panelists:

Ruilin Song, Executive President, PhIRDA

Wei Kang, Managing Director, RDPAC

Dealmaker's Showcase: The Work Starts When the Deal is Done

Cross-border deals are required to capture global economics, but this only can happen if the partners successfully meet the unique challenges of East-West alliance management. These two case studies show how trans-national teams are focused on creating success.

Case Study 1:

Session Chair:

Stephen Hansen, Editor, BioCentury

Panelists:

Jonathan Wang, Chief Business Officer, Zai Lab Ltd.

Arjen Lemmen VP, Corporate Development & Strategy, argenx S.E.

Case Study 2:

Session Chair:

Jeff Cranmer, Executive Editors, BioCentury

Panelists:

Angus Grant, Chief Business Executive, BeiGene Ltd

Jeff Legos, EVP & Global Head of Oncology and Hematology Development, Novartis

The Future of East-West Collaboration: An Investor's Perspective

As Asia biotechs increasingly look to globalize their innovations, many will rely on Western partners to accelerate development and commercialization. In a Fireside Chat with BioCentury, Qiming Managing Partner Nisa Leung discusses the future of East-West collaboration, and how biopharma execs should prepare for success in 2023 and beyond.

Session Chair:

Jeff Cranmer

Nisa Leung, Managing Partner, Qiming Ventures

BONUS CONTENT



Join Jeff Cranmer, Executive Editor, and host of **"BioCentury This Week"** for three exclusive "East-West Biopharma Summit" episodes:

Oct. 26

East-West Biopharma Summit Preview

Nov. 15 & Nov. 16

Jeff Cranmer goes on the road with **"BioCentury This Week"** with special guests discussing highlights of the day from the East-West Biopharma Summit.

BioCentury This Week features in-depth conversations with global leaders who are determining the future of medicine. Past episodes are available on Apple Podcasts, Spotify, Google Podcasts, Overcast, Pocketcasts, Podcast Addict, Castbox, BeyondPod, Downcast, layerFM, Breaker, and RadioPublic.

The BioCentury-BayHelix

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



PREPARE IN ADVANCE FOR SUCCESS

Beginning Oct. 11, 2022, access to two important online portals within your event tool-box becomes available to assist you in making the most out of your event experience







Begin Scheduling
1x1 Meetings

biocenturyeastwest2022.meeting-mojo.com



Accelerate your partnership goals



 Build competitive landscapes fast	 Receive custom alerts and notifications	 Save time with fully integrated data sets
 Analyze detailed company profiles	 Discover emerging companies	 Evaluate key financial metrics of deals

BioCentury's Business Intelligence Platform

provides access to pipelines, financings, and deals to help you better prepare for your 1x1 meetings.

Want to learn more? Schedule an online session with BioCentury for tips on how to use BCIQ at the East-West Summit.:

eastwestsummithelp@biocentury.com



FREQUENTLY ASKED QUESTIONS ABOUT THIS YEAR'S SUMMIT

Should I attend?

The East-West Biopharma Summit is designed to help C-Suite executives and investors rise to the challenges of globalization and form trusted cross-border relationships. You should attend if you are a globally minded biopharma executive or investor from the U.S., Europe, or Asia.

The program is tailored for strategic thinkers. It also includes 1x1 meetings, C-level networking, company presentations and an executive report from Insights Partner McKinsey & Company

What will I learn?

This year's Summit will include two plus days of strategic panels on how to rise to the challenges of globalization. Key topics include:

- Recruiting and retaining diverse cross-border management teams.
- Accessing world-class investors in the U.S., Europe, and Asia.
- Building and financing a MRCT (multiregional clinical trial) strategy.
- Navigating regulatory sea changes in the U.S., Europe, and Asia.
- Choosing between partnering and M&A to globalize product development and commercialization.
- Deciding whether or when a physical presence is required overseas.

And much more.

Are Globalization Challenges Really So New?

Yes. There have never been more emerging biopharmas developing transformational technology, and there has never been more money being invested in the biological revolution. But most of these innovator biotechs cannot create global value chains by themselves.

The urgency to globalize is transforming the entire biopharma ecosystem. The new paradigm, built on relationships, is what will be required to continue beyond the Bridge to Innovation.

What is the Bridge to Innovation, anyway?

It has been the anchor theme for BioCentury's China Healthcare Summit since 2014. Over that time, the Summit has been tracking and measuring the pace of biopharma innovation in Asia. BioCentury and BayHelix call it "Building the Bridge to Innovation." At this year's event, BioCentury and BayHelix pivot to a global platform to understand and overcome today's challenges. As we do so, we will continue to use the Bridge to Innovation theme as an anchor for discussions among decision-makers and investors from the U.S., Europe, and Asia.

Why is the Summit Important?

BioCentury's Summits are THE forum for senior-level decision-makers and investors to debate globalization strategies and form trusted cross-border relationships. There is no other strategic venue of this kind. At this year's event, we pivot to a global platform to understand and overcome today's challenges. For the first time, BioCentury, BayHelix and our partners go East AND West to serve decision-makers and investors:

- Face-to-face in Redwood City, CA; and
- Digital access and virtual 1x1 meetings for participants throughout the world.

The 2022 East-West Biopharma Summit demonstrates the commitment of BioCentury and BayHelix to build a global community – fully supported by face-to-face networking and 1x1 in-person and digital meetings for global attendees.

How Can I Participate?

You can register for the event by visiting www.BioCenturyEastWest.com.

If you are located outside of the U.S. or otherwise unable to join in person in Redwood City, CA, we have you covered! This year's hybrid event allows you unfettered access to all the same event content and presentations through our digital platform. You will have the ability to watch live streams of all East-West sessions plus schedule virtual 1x1 meetings with those attending in person and virtually. In addition, all session recordings are available to watch for 30 days after the event.

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



Are Sponsorship Opportunities Available?

The East-West Biopharma Summit provides global visibility to Sponsors committed to innovation. Several packages are available with benefits including branding, tickets, and panelist opportunities. Please contact our team to learn more. Exclusive packages are filling up quickly, [so contact us today!](#)

Are Presentation Opportunities Available?

Absolutely! Nominations to become part of this year's Presenting Company Class of 2022 are now being accepted. To apply to become a Presenting Company, [click here.](#)

When can I start scheduling 1x1 meetings with conference delegates?

This year there are two days of in-person 1x1 meetings (Nov. 15-16) followed by two days of virtual 1x1 meetings (Nov. 17-18). You may start scheduling meetings on Oct. 11. Before then, please make sure to update your bio and company profile in the 1x1 meeting scheduler so you are ready to schedule meetings.

How can complimentary access to BioCentury's BCIQ platform help me at the East-West Biopharma Summit?

All delegates to the conference receive complimentary access to BioCentury's BCIQ platform starting Oct. 11. BCIQ allows you to research pipelines, deals and financings to determine which companies you would like to meet at the East-West Biopharma Summit. BCIQ also includes a Presenting Company Dashboard that provides BioCentury's analysis of the companies presenting at the East-West Summit. If you are attending the event in-person, please visit the BCIQ Help Desk to learn more about how this tool can help you have a more successful meeting.

I can't attend in-person, can I still attend virtually?

Yes. Digital Access passes are available for anyone who cannot attend in person. A Digital Access pass provide you with full access (live streaming + on-demand recordings) to all panels and presentations at the East-West Biopharma Summit. It also provides you with an opportunity to schedule virtual 1x1 meetings over two full days (Nov. 17-18).

THE BIOCENTURY SHOW

Leveraging 30-years as a leading biopharma intelligence provider, The BioCentury Show premiered in January 2022 as a bimonthly webcast delivering an objective, thoughtful and accurate spotlight of views from key scientific opinion leaders, corporate decision-makers, venture capitalists, patient and consumer groups who stand to benefit the most from the promise of biotechnology.

With a focus on turning science into medicine, the BioCentury Show explores topics of the day. Past guests include:

- **Laura Esserman, M.D.**, Professor of Surgery and Radiology, University of California San Francisco; Director, UCSF Carol Franc Buck Breast Care Center
- **Michael Gaito**, Global Head of Healthcare Investment Banking, J.P. Morgan
- **Scott Gottlieb, M.D.**, Former Commissioner, FDA; Partner, New Enterprise Associates
- **Yvonne Greenstreet**, MBCHB, CEO, Alnylam Pharmaceuticals Inc.
- **Otello Stampacchia, Ph.D.**, Founder and Managing Director, Omega Funds

To View Recent Episodes,
Visit: [BioCenturyShow.com](https://www.biocenturyshow.com)



EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company

NOV
14-16
2022REDWOOD CITY,
CALIFORNIANOV
17-18
2022

VIRTUAL

EVENT ORGANIZERS

BIOCENTURY BioCentury gives biopharma executives, investors and institutions the power to make business-critical decisions through independent, deep-dive analysis; high-quality data; and industry-leading business intelligence, and global events.
www.biocentury.com

BayHelix
G R O U P

The BayHelix Group is a non-profit professional organization of business leaders with a mission to shape the growth of the life sciences and healthcare industry. Founded in 2001 in the San Francisco Bay Area, BayHelix has grown to over 800 members globally with a strong presence in China and the US. BayHelix aspires to foster and create business opportunities, supply and nurture leaders for the community, and network and share information and experience among its members. The diverse membership base covers many of the world's top pharmaceutical and biopharmaceutical companies, leading professional services and investment firms, as well as start-up biotech companies in China and the US. BayHelix membership is by-invitation only. Over two thirds of members are C-level executives. The majority of them are cross trained in science and business as well as bilingual in Chinese and English. BayHelix has become an influential organization that connects emerging biopharmaceutical companies in China to their counterparts around the world. www.bayhelix.org

INSIGHTS PARTNER

**McKinsey
& Company**

We help organizations across the private, public, and social sectors create the Change that Matters most to them. From the C-suite to the front line, we partner with our clients to transform their organizations, embed technology into everything they do, and build enduring capabilities.
www.mckinsey.com

C-SUITE BOOTCAMP HOST

Davis Polk

For many years, Davis Polk has been advising clients in the healthcare and life sciences – from investors to startups to the world's largest pharmaceuticals, biotechnology and diagnostic and medical devices companies – on a full range of transactions and other legal matters. Healthcare and life sciences clients trust in our understanding of the complex issues they face in capital markets, acquisitions, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, internal investigations and litigation. Clients appreciate that our team includes lawyers with strong biomedical backgrounds such as Ph.D.s and biomedical engineering degrees. www.davispolk.com

WELCOME RECEPTION HOST



PANACEA VENTURE
HEALTHCARE

Panacea Venture is a healthcare focused venture capital firm, with offices in Shanghai, Hong Kong, and Silicon Valley. Founded in 2017, Panacea Venture focuses on investing in and incubating early-stage life science companies with breakthrough technologies and discoveries that can potentially address unmet medical needs and enhance the quality of life on a global scale. We currently manage three USD funds and one RMB fund. Our investment team members are located across China, U.S., and Europe, with an extensive coverage of all the major global life sciences hubs. www.panaceaventure.com

NETWORKING RECEPTION HOST



NOVOTECH
The Asia Pacific CRO

Novotech is the leading Asia-Pacific biotech specialist CRO with global execution capabilities. Novotech is a clinical CRO with labs, phase I facilities, and drug development consulting services. It has accumulated experience in over 3,700 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biopharmaceutical clients conducting clinical trials in Asia, the US and globally. With the acquisition of a US based CRO in May 2022, Novotech has over 2500 staff working across our offices in 13 geographies. <https://novotech-cro.com>

ROAD SHOW TRACK HOST

zaiLab™

With precision, persistence and fully integrated development capabilities, Zai Lab is bringing best-in-class and first-in-class medicines to more people around the world, faster. Founded in 2014 by Dr. Samantha Du, Chair and CEO, Zai Lab is striving to uncover new ways to deliver advanced medicines quickly and safely, accelerating solutions people need to triumph over cancer, autoimmune and infectious diseases, and neurological disorders. Zai Lab is a trusted partner of choice for industry-leading global biopharmaceutical companies seeking access to the Chinese market and a long-term strategic collaborator for global clinical development. www.zailaboratory.com

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



BELGIUM TRACK HOSTS

AGIO

/ capital & business solutions

International Financial and Business Solutions - Boots on the Ground / We advise across borders Founded in 2017,

Agio Capital is a financial and business advisory, which together with Agio Legal and Agio Finance, has a staff of over 80 professionals. We are international with a local presence. With our own people, local presence, and strong network in different regions in the world, we know what is really happening.

Headquartered in Europe, Belgium, with offices in Shanghai and Hong Kong, and an additional hub in the US, we cover the main global markets. As such we are well positioned to assist our clients effectively in regional and international transactions.

Our financial services include capital raising (equity and loans), debt restructuring, bankruptcy/insolvency and mergers & acquisitions.

Our business services focus on strategic partnerships, Joint-ventures, in-and out licensing, setting up new companies or deal negotiation. Your success is our success, so our people will do everything to make any project into a success. No compromise, just maximize. www.agiocapsol.com



We facilitate investment projects in Flanders and we give support to Flemish export companies

www.flandersinvestmentandtrade.com/en



The Wallonia Foreign Trade and Investment Agency (AWEX) is the Wallonia - Region of Belgium's government agency in charge of foreign Trade and foreign investment. The agency has a worldwide network of 105 Economic and Trade Attachés.

Wallonia is home to many Biotech and Medtech companies of various sizes, from SMEs to large companies, such as the big players GSK and UCB, including spinoffs, suppliers and service providers.

We are looking for companies and foreign investors who want to be present in Europe and explore all incentives available and the attractiveness of Wallonia as the European Market Entry. www.awex.be/en

SPONSORS



BeiGene BeiGene is a global biotechnology company that is developing and commercializing innovative and affordable oncology medicines to improve treatment outcomes and access for far more patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 8,500 colleagues spans five continents, with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland. www.beigene.com



CBC Group, Asia's largest healthcare-dedicated asset management firm focuses on platform-building, buyout, credit/Royalty, and real estate across healthcare sectors, including pharmaceutical and biotech, medical technology and healthcare services. CBC is committed to creating lasting value by integrating global innovations and talents. Partnering with the world's top entrepreneurs and scientists, its unique "investor-operator" approach has empowered leading healthcare companies to widen access to affordable medical care, catalyze innovations, and improve efficiency in fulfilling unmet medical needs worldwide. Founded in 2014, CBC has built a world class team of investment, industry and portfolio management professionals, headquartered in Singapore with locations across Shanghai, Beijing, Hong Kong, New York, London, and Seoul. www.cbridgecap.com



Founded in 2018, Chemical.AI is one of the world's leading companies leveraging AI and big data to transform

research and development in chemistry with offices in Shanghai, Wuhan and an AIoT lab in Shanghai. ChemAIRS, an artificial intelligence aided synthesis planning platform built by Chemical.AI boosts successful rates in chemical synthesis route design and prediction. It helps chemists quickly find more successful and feasible methods with commercially available starting materials.

Furthermore, ChemAIRS integrates both external (commercially available starting materials) and internal data (including ELN and Building Blocks inventory) to design more appropriate and practical routes. Until now, Chemical.AI has successfully provided its service to many well-known domestic and international big Pharma and top CROs, and formed global alliance. For more information, please go to www.chemical.ai

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



GOODWIN

With more than 1,800 corporate and litigation lawyers working together to support our clients' needs, Goodwin is

shaping the world of law by representing both innovators and investors in a rapidly-changing, technology-driven economy. Our globally recognized Life Sciences Practice represents 1,700+ life sciences clients with specialized sector expertise in biotechnology, pharmaceuticals, medical devices, medical technology, diagnostics, healthcare IT, healthcare services, and consumer products (including foods, supplements and cosmetics) which includes 160+ public company clients. We use law to enable our clients' success and partner with our clients to practice law, with not only integrity, but with ingenuity, agility and ambition.

www.goodwinlaw.com



Shonan Health Innovation Park (Shonan iPark) began operations in April 2018, with the aim of creating a co-location ecosystem comprised of researchers, industry experts, venture startups,

government, and academia who will collaborate and co-create - to accelerate research, with the aim of transforming cutting-edge science into impactful health solutions for patients across the world.

www.shonan-health-innovation-park.com/en



Our mission is to unlock the potential of life science Innovation no matter where it originates. Johnson & Johnson

Innovation teams aim to solve the world's toughest health challenges and drive scientific breakthroughs that improve health for everyone, everywhere. We know that a great idea can come from anywhere and we are proud of our strong track record of cultivating innovation and pairing our deep internal know-how with some of the most promising external innovation from around the globe.

www.jnjinnovation.com



李氏大藥廠

Lee's Pharmaceutical is an Integrated research-driven and market-oriented biopharmaceutical company publicly listed in Hong Kong with over 25 years' experience in the pharmaceutical industry in China. The goal of Lee's Pharmaceutical is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. www.leespharm.com



LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly Innovative biopharmaceutical companies around the world, LianBio is advancing a

diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position itself as a partner of choice with a platform to provide access to China and other Asian markets. www.lianbio.com



LYFE Capital is a global pioneering healthcare investment platform. We believe that "Healthcare has no boundaries", and that every new choice we made has the potential to advance healthcare and solve the unmet needs for

everyone. LYFE Capital leverages our expertise and global resources to invest in and create value for healthcare companies across the globe. Our experienced team has a comprehensive understanding of the global healthcare industry. Management teams value our credibility as we guide them to maximize their potential in a dynamic global market.

www.lyfecapital.com



Merck, a leading science and technology company, operates across life science, healthcare

and electronics. Around 60,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2021, Merck generated sales of € 19.7 billion in 66 countries.

Scientific exploration and responsible entrepreneurship have been key to Merck's technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics. <https://www.merckgroup.com/en>

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



NAN FUNG LIFE SCIENCES

南豐生命科技

Nan Fung Life Sciences, a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. The team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal BioVenture Partners US and Pivotal BioVenture Partners China as well as fund investments, NFLS cover the full spectrum of the life sciences industry including therapeutics, medical devices, and diagnostics and across all development stages.

<https://www.nanfunglifesciences.com>

Neurophth

Neurophth is China's leading in-vivo gene therapy company for ophthalmic diseases. As a clinical-stage company, Neurophth is dedicated to discovering and developing gene therapies for patients suffering from blindness and other eye diseases globally. www.neurophth.com/en



Nucleus Network is Australia's largest Phase 1 clinical research organization and the only Phase 1 specialist globally with facilities in the USA and Australia. Since our establishment in 2004, Nucleus Network has conducted well over 1000

Phase 1 clinical trials for Biotechnology and Pharmaceutical Companies from across the globe, including China, Europe, Japan, South Korea, Taiwan and the USA.

www.nucleusnetwork.com/us/

PAUL HASTINGS

Dedicated to providing intellectual capital and superior execution to the world's leading Wall Street and global investment banks,

asset managers and corporations achieve their business and legal goals, Paul Hastings is a premier global finance law firm with elite teams in finance, mergers and acquisitions, private equity, and litigation. It is one of only a handful of law firms ranked across multiple core finance areas including: structured credit, leveraged finance, private credit, capital markets, and real estate finance. Paul Hastings is ranked as one of the top firms in the world in The American Lawyer's "Premier League" for momentum, profit and prestige amongst firms in the 2022 American Lawyer 100. www.paulhastings.com

P VOTAL BIOVENTURE PARTNERS 鼎豐生科資本

Pivotal bioVenture Partners China, a member of Nan Fung Life Sciences, is a venture capital firm specializing in venture

building in the life sciences industry. Its investment strategy is centered on identifying promising innovative products and technologies and bringing them to serve the growing unmet medical needs in Greater China region by building new ventures. Its investment areas include therapeutics, medical devices and medical services.

<https://www.pivotalbiovp.cn/en>



Qiming Venture Partners Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area.

Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with \$9.4 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.

Qiming Venture Partners is a top-tier VC firm with outstanding reputation. Qiming has been widely recognized by investors from around the world and has become an ideal VC firm for entrepreneurs. With our exceptional investment performances, Qiming has won multiple world-renowned venture capital awards. www.qimingvc.com/en



Russell Reynolds Associates is a leading executive search and leadership advisory firm that helps global CEOs and boards shape what's

next right now. www.russellreynolds.com/en/



Quan capital is a life sciences venture capital firm with strong China expertise and global

capabilities. We discover, incubate, and grow next-generation life science companies in early and growth stage, worldwide. Our portfolio companies pioneer differentiated therapies and enabling technologies to address major human diseases with high unmet medical needs.

Quan has offices in Shanghai, Menlo Park and Boston. Our investment professionals combine their strong expertise in both science and business with their diverse experiences in global drug development and healthcare investments, and they leverage their broad network worldwide to help maximize the company's value across geographies and development stages. www.quancapital.com/en/

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



NOV
14-16
2022

REDWOOD CITY,
CALIFORNIA

NOV
17-18
2022

VIRTUAL



Simcere Pharmaceutical Group (SEHK 2096) is one of the leading fully integrated biopharmaceutical companies

in China, with 40+ products on the market and ~6100+ employees across the globe, total revenue is RMB 5,000 million in 2021, among which revenues of the innovative pharmaceuticals account for 62.4%. Simcere has established extensive collaborations, and has invested \$400 million in global life science companies and VCs. Simcere is actively seeking for licensing/collaboration on development candidates with first-in-class or best-in-class potentials, and commercial products with substantial market opportunities in China and worldwide. <https://en.simcere.com/>



Sidley is a global law firm with over 2,100 lawyers in 21 offices worldwide. Sidley's pioneering

Global Life Sciences practice comprises an experienced team of approximately 200 lawyers across numerous legal disciplines in our offices around the world. We understand the challenges you face in the course of conducting business across the global drug and device supply chain, having counseled high-profile clients in every sector of the dynamic life sciences industry. Advising on the full scope of regulatory, compliance and enforcement, litigation and transactional matters, we can offer you a holistic legal approach that will smooth your path as you navigate industry changes, technological advances, market demands and policy hurdles. <https://www.sidley.com/en/us/>

SUPPORTING ORGANIZATIONS



Biocom California is the leader and advocate for California's life science sector. We work on behalf of more than 1,600 members to drive public

policy, build an enviable network of industry leaders, create access to capital, introduce cutting-edge STEM education programs and create robust value-driven purchasing programs. www.biocom.org



California Life Sciences (CLS) is the state's most influential and impactful life sciences membership organization, advocating for the

sector and its diverse innovation pipeline. For more than 30 years, CLS has served the community by supporting companies of all sizes, from early-stage innovators and startups to established industry leaders in the fields of biotechnology, pharmaceuticals, and medical technology. www.califesciences.org



Since our founding in January, 2007, ChinaBio® Group has successfully helped nearly 100 US, European and Asia-Pacific life science companies achieve success in China. Leveraging our consulting and advisory teams' significant experience in China's life science industry, and our extensive proprietary databases, we have helped our clients identify over 1,400 in-/out- licensing and M&A opportunities and raise over \$500M in funding in China. Our clients have included many global pharma and life science companies as well as early stage and mid-size companies. ChinaBio® Group is headquartered in Shanghai with offices in San Diego, Silicon Valley and Basel, Switzerland. www.chinabio.com



Lingmed Ltd. was founded in 2013 in Hong Kong, currently we have offices in Shanghai and Beijing. Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. www.lingmed.net



Lychee Group is a pioneer of life sciences and healthcare events that bring together key global and domestic players operating in the China market. Since 2008, Lychee Group has played an integral role in launching and managing some of the most recognizable events in the industry including "China Healthcare Investment Conference (CHIC)," "ChinaTrials: Clinical Development Leaders' Summit," "BioCentury & BayHelix's China Healthcare Summit," and "Silicon Valley Bank's Healthcare Capital & Connections Summit." Lychee Group has offices in New Jersey and Shanghai. www.lycheegroup.com



MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep

knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients' cross-border projects: market assessment, in-/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen. msqventures.com

The BioCentury-BayHelix

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



Founded in 1988, China Pharmaceutical Innovation and Research Development Association (PhIRDA) is centering on the principle of "innovation, industrialization, internationalization", build a bridge between the government and our members. PhIRDA persists in innovation to achieve unmet clinical requirements and facilitates the industrialization of pharmaceutical innovation. Now, PhIRDA has 162 members mainly consists of pharmaceutical R&D enterprises, research institutions, clinical institutions, R&D Services companies and investment institutions focusing on pharmaceutical Innovation and established 11 Specialty Committees. PhIRDA is also a member of International Federation of Pharmaceutical Manufacturers & Associations (IFPMA). en.phirda.com



Under the China Association of Enterprises with Foreign Investment (CAEFI), the R&D-based Pharmaceutical Association Committee (RDPAC) is a non-profit organization made up of 45 member companies with pharmaceutical R&D capability. As of June 2020, RDPAC member companies have established 47 manufacturing facilities and 25 R&D centers in mainland China. From July 2015 to June 2020, RDPAC member companies have introduced more than 206 innovative drugs to China market. en.rdpac.org



The Sino-American Pharmaceutical Professionals Association (SAPA) is a non-profit organization. Established in 1993 and headquartered in the center of the pharmaceutical corridor in New Jersey, SAPA rapidly became one of the most active Chinese American professional associations in the US with seven chapters and outreach to over 10,000 pharmaceutical professionals. <https://sapaweb.org>



As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO, biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO, enabling more than 5,850 collaborators from over 30 countries to realize the vision that "every drug can be made and every disease can be treated." www.wuxiapptec.com



Celebrating our 23rd year of BioEquity Europe, the industry's Premier International showcase is where connections are made, relationships are built, and opportunities are uncovered.

Join us May 15-16, 2023 in Dublin, Ireland designed exclusively for the C-Suite of financial dealmakers, biopharma executives, venture capitalists, private investors and policy makers.

Continue building your network well after the event ends with our exclusive two-day digital 1x1 meetings on (May 22-23, 2023).

The Convention Centre Dublin
Dublin, Ireland

BioEquityEurope.com



The BioCentury-BayHelix

EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



NOV
14-16
2022

REDWOOD CITY,
CALIFORNIA


NOV
17-18
2022

VIRTUAL

INITIAL PRESENTING COMPANY CLASS OF 2022



Insilico Medicine



EAST-WEST BIOPHARMA SUMMIT

Organized by BioCentury and BayHelix in collaboration with McKinsey & Company



REGISTER ONLINE — WWW.BIOCENTURYEASYWEST.COM

PAYMENT PROCEDURES

Payment in full is required upon registration and is non-refundable. Every effort is made to ensure that the agenda noted in this brochure is accurate and up to date, but changes beyond BioCentury's control may occur. The program agenda is updated on a regular basis and may be viewed by visiting www.BioCenturyEastWest.com.

BioCentury makes every effort to hold the planned event. In the unlikely occurrence that the event is cancelled or postponed, BioCentury is not responsible for any hotel or travel arrangements that you have made.

EVENT BOOKING — TERMS & CONDITIONS

Registration Fees: A receipt will be forwarded upon registration, unless other arrangements have been made such as payment in foreign currencies. For assistance in paying in RMB, please email eastwestsummithelp@biocentury.com for instructions on how to register. Fees must be paid in full prior to the event. The Fee includes all refreshments breaks, lunch, networking receptions and access to the event digital platform and associated event materials. Please note: If full payment is not received prior to the event start date, admission to the event may be refused.

COVID POLICY

While negative COVID tests are not required, we are requesting that everyone in attendance be vaccinated and that you please be mindful of any symptoms or illness you may have before joining us. Please note that any COVID specific guidelines set by the hotel venue will be honored by BioCentury and we ask event participants to do so as well. For additional information, please visit the [Health & Safety section of our website](#) for updates on COVID mitigation and local regulations.

REGISTRATION / PRICING SCHEDULE

- **Delegate Rate** \$1495*

**Early bird registration is open thru Sept 16 for a rate of \$1295*

- **Qualified Presenting Company** \$3495

GROUP DISCOUNT PRICING

Discounts are available for groups of five (5) or more from any one company. For additional information and pricing, please email:

eastwestsummithelp@biocentury.com

EVENT DIGITAL PLATFORM

BioCentury encourages all participants to make use of the Summit's digital event platform which may be accessed by visiting:

biocenturyeastwest2022.meeting-mojo.com

The platform will be open to all registered participants beginning Oct. 11, 2022 to begin scheduling 1x1 meetings. We recommend that you access the platform per email instructions that you will receive within 24-hours of registering to complete your delegate profile.

For assistance or questions regarding the digital event platform, please email

eastwestsummithelp@biocentury.com

The BioCentury-BayHelix East-West Biopharma Summit will take place at the:

Grand Bay Hotel San Francisco

223 Twin Dolphin Drive
Redwood City, CA 94065
(+1) 650-598-9000

An event room block has been secured by BioCentury for all event delegates with a discounted room rate of \$219/night plus tax. You must make your own reservation and booking under this room block prior to Nov. 1, 2022 to receive the reduced rate.

